Rheumatology
Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
Kichul Shin, Hyun Mi Kwon, Min Jung Kim, Myung Jae Yoon, Hyun Gyung Chai, Seong-Wook Kang, Won Park, Sung-Hwan Park, Chang Hee Suh, Hyun Ah Kim, Seung-Geun Lee, Choong Ki Lee, Sang-Cheol Bae, Yong-Beom Park, Yeong Wook Song
Korean J Intern Med. 2022;37(5):1061-1069. Published online December 13, 2021
Background/Aims: The aim of this study was to investigate long-term post-discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-α inhibitors (TNF-αi) which was then discontinued.
Methods: Sixty Korean patients with RA who participated i..
|
|
Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab
Jeong Seok Lee, Yeong Wook Song, Tae Hwan Kim, Won Tae Chung, Seung Geun Lee, Sung Hwan Park, Gwan Gyu Song, Dae Young Yu, Stephen Xu, Eun Young Lee
Korean J Intern Med. 2018;33(3):622-628. Published online January 20, 2017
Background/Aims: For patients with ankylosing spondylitis (AS), golimumab has consistent efficacy in controlling disease activity over 5 years but its benefit in preventing radiographic progression was less clear at 4 years. To predict radiographic progression, we analyzed the baseline characteristi..
|
|
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
Steven S. Storage, Harsh Agrawal, Daniel E. Furst
Korean J Intern Med. 2010;25(1):1-17. Published online February 26, 2010
English articles on abatacept, golimumab, and tocilizumab in rheumatoid arthritis published between 2002 and 2009 were reviewed systematically. All randomized clinical trials, open-label extensions, meta-analyses, and reviews were examined. There were thirteen articles on abatacept, four on goli..
|
|
|